JUBLPHARMA - JUBILANT PHARMOVA LIMITED Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

JUBLPHARMA

47/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹932.00+5.75(+0.62%)

Market Closed as of Aug 7, 2026, 15:30 IST

Select time range

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 35% return compared to 8.1% by NIFTY 50.

Balance Sheet: Strong Balance Sheet.

Growth: Good revenue growth. With 32% growth over past three years, the company is going strong.

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.

Cons

Technicals: SharesGuru indicator is Bearish.

Momentum: Stock is suffering a negative price momentum. Stock is down -5.8% in last 30 days.

Valuation
Market Cap	14.73 kCr
Price/Earnings (Trailing)	36.77
Price/Sales (Trailing)	1.76
EV/EBITDA	13.17
Price/Free Cashflow	-66.26
MarketCap/EBT	23.97
Enterprise Value	16.68 kCr

Fundamentals
Revenue (TTM)	8.35 kCr
Rev. Growth (Yr)	19.2%
Earnings (TTM)	397.5 Cr
Earnings Growth (Yr)	-21.2%

Profitability
Operating Margin	8%
EBT Margin	7%
Return on Equity	5.6%
Return on Assets	2.56%
Free Cashflow Yield	-1.51%

Growth & Returns
Price Change 1W	-5.4%
Price Change 1M	-5.8%
Price Change 6M	-1.4%
Price Change 1Y	-17.4%
3Y Cumulative Return	35%
5Y Cumulative Return	6.7%
7Y Cumulative Return	11.7%
10Y Cumulative Return	10.8%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-1.26 kCr
Cash Flow from Operations (TTM)	1.23 kCr
Cash Flow from Financing (TTM)	94.9 Cr
Cash & Equivalents	1.27 kCr
Free Cash Flow (TTM)	-222.3 Cr
Free Cash Flow/Share (TTM)	-13.96

Balance Sheet
Total Assets	15.52 kCr
Total Liabilities	8.43 kCr
Shareholder Equity	7.1 kCr
Current Assets	4.11 kCr
Current Liabilities	2.54 kCr
Net PPE	3.51 kCr
Inventory	1.23 kCr
Goodwill	2.83 kCr

Capital Structure & Leverage
Debt Ratio	0.21
Debt/Equity	0.45
Interest Coverage	1.9
Interest/Cashflow Ops	6.79

Dividend & Shareholder Returns
Dividend/Share (TTM)	5
Dividend Yield	0.54%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Technical Indicators
RSI (14d)	19.79
RSI (5d)	0.00
RSI (21d)	38.98
MACD Signal	Sell
Stochastic Oscillator Signal	Buy
SharesGuru Signal	Sell
RSI Signal	Buy
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Description	Share	Value
Radiopharma	42.7%	990 Cr
Contract Development and Manufacturing Organisation - Sterile Injectables	23.6%	546.5 Cr
Contract Research, Development and Manufacturing Organisation	14.4%	334.8 Cr
Allergy Immunotherapy	9.4%	217.6 Cr
Generics	9.2%	214.4 Cr
Unallocable corporate	0.6%	14.8 Cr
Total		2.3 kCr

Shareholder Name	Holding %
SPB TRUSTEE COMPANY PVT LTD	20.08%
HSB TRUSTEE COMPANY PVT LTD	19%
REKHA JHUNJHUNWALA	3.28%
MILLER HOLDINGS PTE LTD	3.28%
MAV MANAGEMENT ADVISORS LLP	3.15%
GOVERNMENT PENSION FUND GLOBAL	3.1%
EAST BRIDGE CAPITAL MASTER FUND I LTD	2.53%
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MULTICAP FUND	2.41%
ABAKKUS EMERGING OPPORTUNITIES FUND-1	1.15%
SBI LIFE INSURANCE CO. LTD	1.11%
NIKITA RESOURCES PRIVATE LIMITED	0.97%
PRIYAVRAT BHARTIA	0.88%
HARI SHANKER BHARTIA	0.23%
SHAMIT BHARTIA	0.08%
KAVITA BHARTIA	0.01%
TORINO OVERSEAS LIMITED	0%
CUMIN INVESTMENTS LIMITED	0%
RANCE INVESTMENT HOLDINGS LIMITED	0%
JUBILANT ENPRO PRIVATE LIMITED	0%
VAM HOLDINGS LIMITED	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.65 LCr	62.14 kCr	+1.40%	+18.90%	38.49	7.49	-	-
DIVISLAB	Divi's Lab	2.23 LCr	11.68 kCr	+22.30%	+30.90%	76.11	19.06	-	-
CIPLA	Cipla	1.18 LCr	29.16 kCr	-0.90%	-2.70%	34.95	4.04	-	-
DRREDDY	Dr. Reddy's Lab	98.32 kCr	34.65 kCr	-13.90%	-3.00%	30.45	2.84	-	-
AUROPHARMA	Aurobindo Pharma	92.92 kCr	35.62 kCr	+1.30%	+49.60%	25.23	2.61	-	-

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	14.5%	8,280	7,234	670	6,282	6,059	6,099
Other Income	16.1%	66	57	6.87	38	82	18
Total Income	14.5%	8,346	7,291	677	6,320	6,141	6,116
Cost of Materials	16.9%	2,320	1,985	182	1,666	1,349	1,349
Purchases of stock-in-trade	5.4%	313	297	24	252	202	168
Employee Expense	19.1%	2,701	2,268	222	2,166	2,043	1,923
Finance costs	-11.7%	212	240	27	188	145	184
Depreciation and Amortization	19.3%	440	369	38	554	382	349
Other expenses	13.5%	1,675	1,476	145	1,462	1,442	1,243
Total Expenses	15%	7,672	6,670	646	6,248	5,501	5,235
Profit Before exceptional items and Tax	8.4%	674	622	32	72	640	881
Exceptional items before tax	-116.8%	-59.2	360	-16.89	-56.82	0	-21.23
Total profit before tax	-37.4%	614	981	15	16	640	860
Current tax	-24.5%	161	213	20	181	173	270
Deferred tax	178.7%	56	-68.9	-10.48	-88.42	45	27
Total tax	51%	217	144	9.78	93	217	297
Total profit (loss) for period	-52.5%	398	836	7.27	-64.88	413	836
Other comp. income net of taxes	548.8%	546	85	5.44	220	244	174
Total Comprehensive Income	2.4%	943	921	13	156	657	1,010
Earnings Per Share, Basic	-53.5%	25.15	52.99	4.87	-3.83	26	52.48
Earnings Per Share, Diluted	-53.6%	25.08	52.85	4.86	-3.83	26	52.48
Debt equity ratio	-	-	-	-	-	-	0
Debt service coverage ratio	-	-	-	-	-	-	0
Interest service coverage ratio	-	-	-	-	-	-	0

Description	(%) Q/Q	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024
Revenue From Operations	7.9%	2,290	2,122	1,966	1,901	1,929	1,822
Other Income	21.1%	24	20	9.8	12	12	9.2
Total Income	8%	2,314	2,143	1,976	1,913	1,941	1,831
Cost of Materials	8.6%	643	592	565	520	584	467
Purchases of stock-in-trade	2.5%	84	82	74	73	85	81
Employee Expense	8.7%	767	706	636	591	591	560
Finance costs	0%	56	56	50	49	53	56
Depreciation and Amortization	-3.3%	117	121	105	98	95	91
Other expenses	14.7%	470	410	392	402	367	400
Total Expenses	5.7%	2,124	2,010	1,780	1,758	1,731	1,681
Profit Before exceptional items and Tax	43.2%	190	133	196	154	209	150
Exceptional items before tax	63.9%	-13.7	-39.7	-5.8	0	-3.3	-18.9
Total profit before tax	88.2%	176	94	190	154	206	131
Current tax	209.5%	66	22	36	38	115	32
Deferred tax	-165.3%	-8.8	16	34	14	-60.1	-2.5
Total tax	51.4%	57	38	70	52	55	30
Total profit (loss) for period	114.5%	119	56	120	102	151	101
Other comp. income net of taxes	360.7%	282	62	160	41	-4.6	64
Total Comprehensive Income	241.9%	401	118	280	144	147	164
Earnings Per Share, Basic	159.9%	7.55	3.52	7.59	6.49	9.71	6.37
Earnings Per Share, Diluted	158.7%	7.52	3.52	7.57	6.47	9.68	6.36

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	-64.7%	264	746	785	810	88	2,710
Other Income	-98.6%	2.4	100	103	138	126	48
Total Income	-68.6%	266	845	888	948	214	2,757
Cost of Materials	-100.4%	0	282	310	396	0	1,329
Purchases of stock-in-trade	-	0	0	6.5	15	0	66
Employee Expense	-49%	104	203	190	167	49	221
Finance costs	-78.3%	7.3	30	30	19	31	102
Depreciation and Amortization	-90.4%	6	53	48	43	6.25	100
Other expenses	-53%	111	235	223	225	45	611
Total Expenses	-71.4%	228	796	846	869	131	2,484
Profit Before exceptional items and Tax	-22.9%	38	49	42	79	82	273
Exceptional items before tax	20.5%	-8.7	-11.2	0	0	0	0
Total profit before tax	-24.3%	29	38	42	79	82	273
Current tax	-81.1%	4.6	20	6.8	14	14	45
Deferred tax	254.2%	4.7	-1.4	3.3	16	-9.91	13
Total tax	-51.2%	9.3	18	10	29	3.75	59
Total profit (loss) for period	244.4%	63	19	32	50	78	214
Other comp. income net of taxes	-46.2%	-0.9	-0.3	-0.5	1.32	0.02	-1.75
Total Comprehensive Income	238.9%	62	19	31	51	79	213
Earnings Per Share, Basic	1314.3%	3.97	1.21	1.99	3.13	4.93	13.47
Earnings Per Share, Diluted	1314.3%	3.97	1.21	1.99	3.13	4.93	13.47
Debt equity ratio	-	-	-	-	-	-	0
Debt service coverage ratio	-	-	-	-	-	-	0
Interest service coverage ratio	-	-	-	-	-	-	0

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	103.5%	1,267	623	1,088	1,077	96	974
Loans, current	-30.8%	1.9	2.3	1.1	1.2	0.08	1
Total current financial assets	44.3%	2,558	1,773	2,142	2,085	212	2,002
Inventories	0.3%	1,232	1,228	1,129	1,162	129	1,328
Current tax assets	-28.6%	71	99	18	37	1.67	24
Total current assets	21%	4,109	3,397	3,510	3,502	363	3,606
Property, plant and equipment	8.3%	3,510	3,242	2,132	2,128	216	2,250
Capital work-in-progress	26.4%	2,962	2,344	2,715	1,857	125	1,095
Investment property	-	0	0	0	0	0	0
Goodwill	6.7%	2,826	2,649	2,541	2,480	246	2,452
Non-current investments	66.7%	61	37	36	34	3.44	33
Loans, non-current	0%	0.3	0.3	0.3	0.3	0.03	0.4
Total non-current financial assets	38.5%	91	66	63	56	5.45	54
Total non-current assets	13.4%	11,413	10,062	9,179	8,423	767	7,793
Total assets	14.8%	15,523	13,521	12,756	11,924	1,155	11,400
Borrowings, non-current	28.2%	2,972	2,319	2,150	2,542	317	3,170
Total non-current financial liabilities	26%	4,106	3,258	2,924	2,878	338	3,392
Provisions, non-current	20.5%	160	133	119	102	10	93
Total non-current liabilities	21.1%	5,888	4,861	4,353	4,051	424	4,208
Borrowings, current	-11.5%	248	280	287	283	25	250
Total current financial liabilities	25%	2,084	1,668	1,866	1,704	162	1,589
Provisions, current	17.7%	94	80	78	65	6.64	73
Current tax liabilities	-5%	20	21	18	7.7	3.7	11
Total current liabilities	21.6%	2,539	2,088	2,165	1,947	189	1,790
Total liabilities	21.3%	8,427	6,950	6,518	5,997	613	5,998
Equity share capital	0%	16	16	16	16	1.58	16
Non controlling interest	108.7%	2.8	-19.8	-16.3	-13.5	-1.28	-8.7
Total equity	8%	7,096	6,572	6,239	5,927	542	5,401
Total equity and liabilities	14.8%	15,523	13,521	12,756	11,924	1,155	11,400

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	-18.2%	10	12	13	20	36	11
Loans, current	0%	0.1	0.1	0.2	0.2	0.1	0.1
Total current financial assets	38.9%	51	37	220	151	240	226
Inventories	-	0	0	232	255	251	276
Total current assets	-7.4%	51	55	484	451	541	565
Property, plant and equipment	-2.1%	95	97	515	522	523	493
Capital work-in-progress	43.7%	5.6	4.2	19	26	37	59
Goodwill	-	0	0	137	137	137	137
Non-current investments	0.2%	2,176	2,172	1,657	1,657	1,657	1,657
Loans, non-current	-	0	0	0.2	0.2	0.2	0.3
Total non-current financial assets	0.2%	2,184	2,180	1,668	1,669	1,668	1,668
Total non-current assets	2.6%	2,382	2,321	2,425	2,441	2,451	2,449
Total assets	2.4%	2,433	2,376	2,910	2,892	2,992	3,014
Borrowings, non-current	0%	50	50	233	244	246	250
Total non-current financial liabilities	2%	52	51	254	267	247	282
Provisions, non-current	29.4%	12	9.5	28	27	27	24
Total non-current liabilities	-3.1%	64	66	281	295	302	306
Borrowings, current	-	0	0	73	78	96	123
Total current financial liabilities	-11.4%	32	36	268	249	282	327
Provisions, current	22.9%	5.3	4.5	8.3	6.8	6.9	10
Current tax liabilities	0%	13	13	13	0.2	0.2	0.2
Total current liabilities	-12.5%	57	65	310	298	315	368
Total liabilities	-9.2%	120	132	592	593	617	674
Equity share capital	0%	16	16	16	16	16	16
Total equity	3%	2,312	2,244	2,318	2,299	2,374	2,340
Total equity and liabilities	2.4%	2,433	2,376	2,910	2,892	2,992	3,014

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	-11.7%	212	240	27	188	145	-
Change in inventories	-159.6%	-44.9	78	9.08	-64.68	-95.65	-
Depreciation	19.3%	440	369	38	554	382	-
Unrealised forex losses/gains	-722.2%	-6.4	0.1	0.14	-5.35	40	-
Adjustments for interest income	-33.3%	25	37	2.61	9.83	2.45	-
Share-based payments	233.3%	12	4.3	0.85	3.65	1.12	-
Net Cashflows from Operations	9.6%	1,436	1,310	118	865	1,032	-
Income taxes paid (refund)	-12.2%	209	238	21	204	194	-
Net Cashflows From Operating Activities	14.5%	1,227	1,072	97	661	838	-
Cash receipts from share of profits of partnership firm or association of persons or LLP	-	0	0	0	8.82	0	-
Proceeds from sales of PPE	2425%	102	5	0.97	19	3.52	-
Purchase of property, plant and equipment	29.9%	1,449	1,116	90	814	600	-
Proceeds from sales of investment property	-	0	0	0	0	44	-
Purchase of investment property	-	0	0	0	0	2.32	-
Proceeds from government grants	-87.2%	79	610	23	244	0	-
Interest received	-37.8%	24	38	2.57	9.98	4.02	-
Other inflows (outflows) of cash	-1261.5%	-16.7	-0.3	2.66	-0.14	170	-
Net Cashflows From Investing Activities	-358.9%	-1,260	488	-60.79	-544.41	-380.37	-
Payments to acquire or redeem entity's shares	-121.7%	0	5.6	0	0	0	-
Proceeds from exercise of stock options	-900%	0	0.9	0	0	0	-
Proceeds from borrowings	9784.6%	2,571	27	12	3,005	247	-
Repayments of borrowings	88.3%	2,070	1,100	14	2,773	5	-
Payments of lease liabilities	18.6%	71	60	6.12	70	60	-
Dividends paid	0%	80	80	7.98	80	80	-
Interest paid	0.9%	238	236	24	234	135	-
Other inflows (outflows) of cash	-	-18	0	-2.74	-3.97	0	-
Net Cashflows from Financing Activities	106.5%	95	-1,452.7	-43.25	-156.69	-32.6	-
Effect of exchange rate on cash eq.	383.3%	117	25	1.16	71	57	-
Net change in cash and cash eq.	35.9%	179	132	-5.75	30	482	-

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	-58.6%	13	30	30	19	31	-
Change in inventories	-395.8%	-34.5	13	63	9.58	0	-
Depreciation	-51.9%	26	53	48	43	6.25	-
Unrealised forex losses/gains	-173.9%	-0.7	3.3	1.2	0.44	0.01	-
Dividend income	-105.6%	0	19	33	97	97	-
Adjustments for interest income	-125%	0.9	1.4	0.5	0.53	0.86	-
Share-based payments	-54.5%	1.5	2.1	1.7	0.97	0.5	-
Net Cashflows from Operations	-38.8%	91	148	154	-47.67	13	-
Income taxes paid (refund)	-56.4%	5.8	12	12	17	19	-
Other inflows (outflows) of cash	-	8.7	0	1	0	0	-
Net Cashflows From Operating Activities	-31.1%	94	136	143	-65.12	-6.47	-
Cashflows used in obtaining control of subsidiaries	-	0	0	0	8.75	0	-
Proceeds from sales of PPE	-	0	0	0	0.92	0.04	-
Purchase of property, plant and equipment	-5%	20	21	68	60	1.95	-
Proceeds from sales of investment property	-66.7%	0	0.4	0.9	0	0	-
Cash receipts from repayment of advances and loans made to other parties	-	0	0	0	0.05	0	-
Dividends received	-105.6%	0	19	33	97	97	-
Interest received	-100%	1	1.4	0.3	0.58	0.87	-
Other inflows (outflows) of cash	-2092.3%	-27.5	-0.3	-0.1	-0.12	0	-
Net Cashflows From Investing Activities	1100%	34	-2.3	-40.3	31	96	-
Proceeds from borrowings	-	70	0	100	128	6	-
Repayments of borrowings	180.6%	102	37	34	0	0	-
Payments of lease liabilities	-47.8%	5.7	10	9.4	6.76	2.93	-
Dividends paid	0%	80	80	80	80	80	-
Interest paid	-58.6%	13	30	30	18	30	-
Other inflows (outflows) of cash	-	0	0	-25	0	0	-
Net Cashflows from Financing Activities	17%	-129.9	-156.8	-77.8	23	-107.37	-
Net change in cash and cash eq.	86.5%	-2.3	-23.5	25	-11.54	-17.82	-

Description	(%) Q/Q	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024
Revenue From Operations	4.5%	70	67	66	60	217	196
Other Income	16.7%	0.5	0.4	0.8	0.7	18	18
Total Income	4.5%	71	68	67	60	235	214
Cost of Materials	-	0	0	0	0	78	77
Purchases of stock-in-trade	-	0	0	0	0	0	0
Employee Expense	-14.3%	25	29	27	23	51	52
Finance costs	0%	0.9	0.9	2.5	3	7	7.4
Depreciation and Amortization	-50%	1.3	1.6	1.6	1.5	13	13
Other expenses	20%	31	26	28	26	60	57
Total Expenses	0%	58	58	59	54	212	206
Profit Before exceptional items and Tax	33.3%	13	10	8.5	6.5	24	8.7
Exceptional items before tax	-	-8.7	0	0	0	0	0
Total profit before tax	-65.6%	4.1	10	8.5	6.5	24	8.7
Current tax	-200%	0.2	1.8	1.4	1.2	8.2	6.3
Deferred tax	-7857.1%	-53.3	1.7	55	1.2	1.7	-2.9
Total tax	-2264%	-53.1	3.5	56	2.4	9.9	3.4
Total profit (loss) for period	900%	57	6.6	-6.4	5.8	14	5.3
Other comp. income net of taxes	-22.2%	-0.1	0.1	-0.8	-0.1	0.3	-0.2
Total Comprehensive Income	882.5%	57	6.7	-7.2	5.7	14	5.1
Earnings Per Share, Basic	546.6%	3.59	0.42	-0.4	0.36	0.86	0.33
Earnings Per Share, Diluted	546.6%	3.59	0.42	-0.4	0.36	0.86	0.33

JUBLPHARMA - JUBILANT PHARMOVA LIMITED Share Price

JUBLPHARMA

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

JUBLPHARMA

JUBLPHARMA - JUBILANT PHARMOVA LIMITED Share Price

JUBLPHARMA

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

JUBLPHARMA

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does JUBILANT PHARMOVA LIMITED do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does JUBILANT PHARMOVA LIMITED do?

Important Disclosure & Data Context